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ABSTRACT
ObjeCtive
To compare the effectiveness of the oxytocin receptor 
antagonist atosiban with the beta mimetic fenoterol as 
uterine relaxants in women undergoing external 
cephalic version (ECV) for breech presentation.
Design
Multicentre, open label, randomised controlled trial.
setting
Eight hospitals in the Netherlands, August 2009 to 
May 2014.
PartiCiPants
830 women with a singleton fetus in breech 
presentation and a gestational age of more than 34 
weeks were randomly allocated in a 1:1 ratio to either 
6.75 mg atosiban (n=416) or 40 μg fenoterol (n=414) 
intravenously for uterine relaxation before ECV.
Main OutCOMe Measures
The primary outcome measures were a fetus in cephalic 
position 30 minutes after the procedure and cephalic 
presentation at delivery. Secondary outcome measures 
were mode of delivery, incidence of fetal and maternal 
complications, and drug related adverse events. All 
analyses were done on an intention-to-treat basis.
results
Cephalic position 30 minutes after ECV occurred 
significantly less in the atosiban group than in the 
fenoterol group (34% v 40%, relative risk 0.73, 95% 
confidence interval 0.55 to 0.93). Presentation at birth 
was cephalic in 35% (n=139) of the atosiban group and 
40% (n=166) of the fenoterol group (0.86, 0.72 to 
1.03), and caesarean delivery was performed in 60% 
(n=240) of women in the atosiban group and 55% 
(n=218) in the fenoterol group (1.09, 0.96 to 1.20). No 
significant differences were found in neonatal 
outcomes or drug related adverse events.
COnClusiOns
In women undergoing ECV for breech presentation, 
uterine relaxation with fenoterol increases the rate of 
cephalic presentation 30 minutes after the procedure. 
No statistically significant difference was found for 
cephalic presentation at delivery.
trial registratiOn
Dutch Trial Register, NTR 1877.
Introduction
Breech presentation occurs in up to 4% of singleton 
pregnancies at term. Since publication of the Term 
Breech Trial in 2000, elective caesarean section has 
been the dominant mode of delivery in most coun-
tries.1-3  In 2015 the World Health Organization reported 
that globally caesarean delivery was overused.4 5 
Breech presentation is the third most common indica-
tion for elective caesarean delivery.6  External cephalic 
version (ECV) is a safe obstetrical procedure that 
reduces the risk of a non-cephalic birth and caesarean 
delivery by approximately 50%.7  In 2014 the American 
College of Obstetricians and Gynaecologists and the 
Society for Maternal-Fetal Medicine published a joint 
consensus statement on the safe prevention of elective 
caesarean delivery, in which ECV is highly recom-
mended.6  This is especially relevant in low and middle 
income countries where the effects of caesarean deliv-
ery on morbidity and mortality are more severe.8
Several methods have been proposed to enhance the 
outcome of ECV, including uterine relaxation with toco-
lytic drugs, epidural or spinal analgesia, and amnio-in-
fusion, as well as complementary methods such as 
vibro-acoustic stimulation, acupuncture, and moxibus-
tion.9  Drug induced uterine relaxation using nitric 
oxide, beta mimetics, calcium channel antagonists, or 
oxytocin receptor antagonists, can increase the success 
rate of ECV.6 10  Most studies evaluating the effectiveness 
of tocolysis have used beta mimetics (nine studies of 
beta mimetics versus placebo, pooled relative risk 1.6 
(95% confidence interval 1.2 to 2.0) for cephalic presen-
tation after ECV attempt).9  However, beta mimetics 
have known adverse maternal cardiovascular side 
effects such as flushing and palpitations.9
Randomised trial data show that nifidepine, a cal-
cium channel blocker, is not effective for increasing 
cephalic presentation after ECV compared with no 
drugs (1.1, 0.85 to 1.5).11 Atosiban, an oxytocin receptor 
antagonist, has no cardiovascular side effects and is 
WhAT IS AlReAdy knoWn on ThIS TopIC
Breech presentation occurs in 3-4% of singleton pregnancies at term, and elective 
caesarean delivery is the dominant mode of delivery in most countries
External cephalic version (ECV) is a relatively safe obstetrical procedure that 
reduces the risk of a non-cephalic birth and caesarean delivery
Beta mimetics are widely used to enhance the success rate of ECV, but they have 
known maternal cardiovascular side effects. Atosiban could be an alternative
WhAT ThIS STudy AddS
Uterine relaxation with fenoterol compared with atosiban results in a higher rate of 
fetuses in cephalic position after ECV
Cephalic presentation at delivery was not significantly different between groups
The frequency of both poor neonatal and poor maternal outcomes did not differ 
between groups; emergency delivery occurred twice in the fenoterol group
Side effects occurred more often in the fenoterol group than in the atosiban group
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becoming more widely used for ECV, yet no randomised 
controlled trial has assessed its effectiveness. We com-
pared the effectiveness of atosiban with the beta 
mimetic fenoterol for achieving a cephalic presentation 
30 minutes after ECV and cephalic presentation at 
delivery.
Methods
study design and participants
We performed a multicentre, open label, randomised 
controlled trial in one academic and seven teaching 
hospitals in the Netherlands. Together, these hospitals 
are responsible for 16 000 increased risk deliveries a 
year, with annual hospital delivery rates ranging from 
1500 to 3000. We followed the CONSORT guidelines to 
report this study.
Women with a singleton fetus in breech position who 
were scheduled for ECV were eligible for the study. 
Exclusion criteria were maternal age less than 18 years, 
gestational age less than 32 weeks, any contraindica-
tion to vaginal birth (such as placenta praevia), any 
contraindication for ECV according to the Guideline of 
the Dutch Association for Obstetrics and Gynaecology 
(scarred uterus other than transverse in the lower seg-
ment, known uterine anomalies, history or signs of pla-
cental abruption, severe pre-eclampsia or HELLP 
syndrome, bleeding less than seven days before ECV 
attempt, and ruptured membranes),12 any known con-
traindication to one of the two study drugs, suspected 
intrauterine growth restriction (defined as estimated 
fetal weight less than the fifth centile for gestational age 
assessed by ultrasonography), severe oligohydramnios 
(deepest pool <2 cm), fetal anomalies, or non-reassur-
ing fetal heart rate. Midwives, residents, or gynaecolo-
gists identified eligible women. After counselling and 
reading the patient information form, patients were 
asked for written informed consent.
randomisation
The women were randomly allocated (1:1) to receive ato-
siban (intervention group) or fenoterol (control group). 
An independent data manager assigned the women to 
groups based on a computer generated random 
sequence, stratified by hospital and parity. EVC was 
scheduled within seven days after randomisation. Par-
ticipants and investigators were aware of allocation; 
blinding was not possible owing to obvious maternal 
side effects that commonly occur with fenoterol, such 
as tachycardia, dizziness, and flushing.
interventions
In each hospital, a team of experienced obstetricians 
and midwives performed the ECV. A trained sonogra-
pher, obstetrician, or midwife carried out ultrasonogra-
phy to assess the position of the fetus, including type of 
breech (frank, complete, or footling), location of the 
placenta, estimation of fetal weight, and estimation of 
amniotic fluid volume, including measurement of the 
largest pocket depth. Fetal wellbeing was established 
with electronic fetal heart rate monitoring for at least 30 
minutes before and after ECV. Fifteen minutes before 
ECV a doctor gave the mother an intravenous bolus of 
atosiban (6.75 mg) or fenoterol (40 μg). ECV could com-
prise a forward and a backward roll. Fetal heart rate was 
monitored intermittently with ultrasonography. The 
duration of any fetal bradycardia was registered. Women 
with non-sensitised Rh negative blood received anti-D 
immunoglobulin (1000 IU intramuscularly) after ECV.
Outcomes
The primary outcome measures were cephalic presenta-
tion 30 minutes after the procedure, confirmed by ultra-
sonography, and cephalic presentation at delivery. 
Secondary outcomes were mode of delivery, incidence 
of fetal and maternal complications, and study drug 
related adverse events. Complications were persistent 
non-reassuring fetal heart rate on cardiotocography, 
occult or overt umbilical cord prolapse, placental 
abruption, and emergency delivery. Adverse events due 
to atosiban or fenoterol were chest pain, nausea, vomit-
ing, headache, flushing, dizziness, hypotension (asso-
ciated with fainting or abnormalities of fetal heart rate), 
tachycardia resulting in palpitations, local skin reac-
tion on injection of the drug, anaphylactic shock, and 
cessation of treatment because of side effects.
Post hoc outcomes were gestational age at delivery, 
time to delivery, admission to neonatal intensive care 
for more than 24 hours, Apgar score less than 7 at five 
minutes, birth weight, blood loss, and maternal blood 
transfusion, postpartum hospital stay (in days), and 
postpartum complications, defined as puerperal fever, 
(suspected) endometritis, mastitis, operation for 
removal of placental tissue, or pulmonary embolism. 
Appendix table 1 lists all outcomes.
The data were collected on web based electronic case 
record forms, and uploaded cases were stored in a data-
base. Paper delivery forms were supplied to partici-
pants who did not deliver in a participating hospital, 
and their primary caretakers, such as midwives in pri-
mary care settings, were asked to ensure that these 
forms were returned after the study.
sample size
The trial was designed to detect a 10% improvement in 
the primary outcome of cephalic presentation 30 min-
utes after ECV, assuming a 50% success rate in the feno-
terol group (β error 20%, α error 5%, two sided test). We 
calculated that 806 women needed to be randomised to 
show an improvement from 50% to 60% with atosiban.
analysis
To ensure intention-to-treat analysis, we carried out five 
imputations on the primary outcome using baseline 
covariates. The primary analysis was subsequently per-
formed on imputed datasets, and we pooled estimates 
from these datasets using Rubin’s rule. Complete case 
analysis was used to analyse secondary outcomes. 
Baseline data were analysed descriptively for the 
women and their pregnancies. The χ2 test was used to 
compare the rates of the primary and secondary out-
comes between the two groups. We considered a P value 
of less than 0.05 to indicate statistical significance. For 
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each outcome we calculated relative risks and appropri-
ate 95% confidence intervals.
We performed three retrospective sensitivity analy-
ses for the primary outcome of cephalic presentation 
30 minutes after ECV. The first was a complete case 
analysis. The second sensitivity analysis was per-
formed because of an imbalance in baseline character-
istics despite randomisation. We adjusted the imputed 
data for age, parity, gestational age at ECV, ethnicity, 
body mass index, estimated fetal weight, type of 
breech presentation, location of the placenta, and 
estimated amniotic fluid index. A third retrospective 
analysis was performed to evaluate the robustness of 
the treatment effect on cephalic presentation 30 min-
utes after ECV between centres. The results were 
pooled into relative risks, and heterogeneity was 
explored in a random effects meta-analysis model. To 
evaluate safety, an interim analysis was planned for 
when half of the patients had been recruited. Serious 
adverse events were reported to an independent data 
safety monitoring board. They noted no conditions to 
stop the trial.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. The results will be used in 
a guideline and will be added to patient information 
brochures.
Results
Between August 2009 and May 2014, 830 women were 
enrolled and randomised; 416 to atosiban (intervention 
group) and 414 to fenoterol (control group). The mean 
gestational age at which ECV was performed was 36 
weeks, and 62% of the women were nulliparous. Base-
line characteristics were comparable between the two 
groups (table 1 ). For the complete case analysis,  primary 
outcome data were available for 410 women in the ato-
siban group and 408 in the fenoterol group (fig 1).
The primary outcome of cephalic presentation 30 
minutes after ECV occurred in 34% (n=140) of women in 
the atosiban group compared with 40% (n=166) in the 
fenoterol group (0.73, 0.55 to 0.93). At delivery, 35% 
(n=139) of fetuses in the atosiban group and 40% 
(n=160) in the fenoterol group were in the cephalic posi-
tion (0.86, 0.72 to 1.03). Caesarean delivery was per-
formed in 60% (n=240) of women in the atosiban group 
and 55% (n=218) in the fenoterol group (1.09, 0.96 to 
1.22; table 2).
In the atosiban group, of the 139 women with a fetus 
in the cephalic position at delivery, 109 (78%) had a 
spontaneous vaginal delivery, 15 (11%) an instrumental 
delivery, and 9 (6%) an intrapartum caesarean delivery. 
In the fenoterol group, of the 160 women with a fetus in 
the cephalic position at delivery, 125 (78%) had a spon-
taneous vaginal delivery, 13 (8%) an instrumental deliv-
ery, and 19 (12%) an intrapartum caesarean delivery. 
Emergency caesarean delivery for suspected fetal dis-
tress was more common in the fenoterol group: two 
cases immediately after ECV and 19 during labour. In 
the atosiban group, four of the 204 women who had 
planned a vaginal birth had emergency caesarean deliv-
ery for suspected intrapartum fetal distress compared 
with 19 of 218 participants in the fenoterol group (rela-
tive risk 0.75, 95% confidence interval 0.24 to 1.29).
table 1 | baseline characteristics of study participants by intervention group for complete 
case analysis. values are numbers (percentages) unless stated otherwise
Characteristics atosiban (n=410) Fenoterol (n=408)
Mean (SD) age (years) 32.1 (4.0) 32.4 (4.3)
Multiparous women 154 (38) 153 (37)
Mean (SD) gestational age at ECV (weeks) 35.8 (0.9) 35.9 (1.0)
White ethnicity 350 (85.4) 355 (87.0)
Mean (SD) body mass index 24.1 (4.3) 24.2 (4.8)
Mean (SD) estimated fetal weight (g)* 2622 (391.0) 2572 (457.5)
Frank breech presentation† 300 (76) 273 (70)
Anterior placenta‡ 127 (33) 144 (37)
Mean (SD) estimated amniotic fluid index§ 13.8 (4.9) 13.7 (4.7)
ECV=external cephalic version.
*Missing data: n=234 for atosiban, n=250 for fenoterol.
†Missing data: n=392 for atosiban, n=391 for fenoterol.
‡Missing data: n=386 for atosiban, n=386 for fenoterol.
§Missing data: n=263 for atosiban, n=281 for fenoterol.
Allocated to fenoterol (n=414): 
  Received allocated intervention (n=413)
  Did not receive allocated intervention (n=1)
Allocated to atosiban (n=416): 
  Received allocated intervention (n=416)
  Did not receive allocated intervention (n=0)
Assessed for eligibility (n=910)
Randomised (n=830)
Lost to follow-up (n=6)Lost to follow-up (n=6)
Intention-to-treat analysis (n=414)
Complete case analysis (n=408)
Intention-to-treat analysis (n=416)
Complete case analysis (n=410)
Excluded (n=80):
  Not meeting inclusion criteria (n=18)
  Declined to participate (n=58) 
  Declined ECV (n=4)
Fig 1 | randomisation, treatment, and follow-up of participants






relative risk  
(95% Ci)
Cephalic presentation 30 minutes after ECV (No; %)* 140 (34) 166 (40) 0.73 (0.55 to 0.93)
Cephalic presentation at delivery (No; %)† 139 (35) 160 (40) 0.86 (0.72 to 1.03)
Mode of delivery‡
Vaginal delivery (No; %): 163 (40) 180 (45) 0.89 (0.76 to 1.05)
 Spontaneous 146 167
 Instrumental 17 13
Caesarean delivery (No; %): 240 (60) 218 (55) 1.09 (0.96 to 1.22)
 Elective 199 158
 No progress of labour 27 26
 Suspected fetal distress 4 21
 Other 10 13
ECV=external cephalic version.
*Imputation for primary outcome.
†Missing data: n=402 for atosiban, n=397 for fenoterol.
‡Missing data: n=403 for atosiban, n=398 for fenoterol.
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The frequency of poor fetal and maternal complica-
tions did not differ between the two groups (table 3). 
The average time between ECV and delivery was 22 
days in both groups. Labour was induced only for addi-
tional indications such as hypertension. No perinatal 
or neonatal mortality occurred in the atosiban group, 
whereas two children died in the fenoterol group. One 
neonate, born five weeks after ECV, died of an autoso-
mal recessive congenital disorder. The other baby died 
two hours after a vacuum assisted delivery for pro-
longed second stage of labour. ECV had been per-
formed five weeks before labour. The baby had normal 
Apgar scores (9 at five minutes), and autopsy did not 
reveal cause of death.
The frequency of fetal and maternal complications 
after ECV did not differ significantly between groups 
(table 4). No woman required emergency delivery in 
the atosiban group but two did in the fenoterol group. 
In one woman, the fetal heart rate was non-reassuring 
after an ECV attempt, and in the other woman, ultraso-
nography showed the umbilical cord to be lying in 
front of the fetal head after successful ECV. No drug 
related adverse events were reported in the atosiban 
group. The procedure was stopped in one woman in 
the fenoterol group because she experienced severe 
hypotension. A significant difference in side effects 
was found between the groups, with 15 women (5%) in 
the atosiban group compared with 209 women (71%) 
in the fenoterol group experiencing palpitations (0.07, 
0.04 to 0.12).
Complete case analysis showed a significant differ-
ence in favour of fenoterol for cephalic presentation 







relative risk  
(95% Ci) P value
Mean (SD) gestational age at delivery (weeks) 38.9 (1.3) 38.9 (1.9) 0.70
Mean (SD) mean time to delivery (days) 22 (9.1) 22 (9.6) - 0.23
Fetal mortality 0 (0.0) 0 (0.0) - -
Neonatal mortality 0 (0.0) 2 (0.1) - 0.15
Admission to neonatal intensive care for >24 hours* 16 (0.4) 17 (0.4) 0.94 (0.48 to 1.8) -
Apgar score <7 at 5 minutes† 6 (1) 13 (3) 0.45 (0.17 to 1.20) -
Mean (SD) birth weight (g)‡ 3356 (460) 3364 (523) - 0.81
Female 204 (50) 204 (50) 1.00 (0.87 to 1.14) -
Mean (SD) blood loss (mL)§ 474 (473.2) 470 (447.3) - 0.92
Women requiring blood transfusions¶ 6 (1) 7 (2) 0.86 (0.29 to 2.5) -
Mean (SD) maternal postpartum hospital stay (days)** 290 (3.1) 287 (3.1) - 0.94
Maternal postpartum complications†† 15 (4) 16 (4) 0.94 (0.74 to 1.9) -
*Missing data: n=399 for atosiban, n=397 for fenoterol.
†Missing data: n=399 for atosiban, n=397 for fenoterol.
‡Missing data: n=394 for atosiban, n=396 for fenoterol.
§Missing data: n=390 for atosiban, n=389 for fenoterol.
¶Missing data: n=400 for atosiban, n=401 for fenoterol.
**Missing data: n=398 for atosiban, n=395 for fenoterol.
††Missing data: n=385 for atosiban, n=386 for fenoterol. Complications: puerperal fever, (suspected) endometritis, mastitis, operation for remove 
placental tissue, and pulmonary embolism.
table 4 | Complications of external cephalic version (eCv) and drug related adverse events in complete case analysis. 






relative risk  
(95% Ci)
Non-reassuring fetal heart rate after ECV attempt resulting in emergency delivery* 0 (0.0) 1 (0.2) -
Placental abruption† 1 (0.2) 0 (0.0) -
Emergency delivery‡ 0 (0.0) 2 (0.4) -
Adverse events due to medication§ 0 (0.0) 1 (0.2) -
Cessation of treatment due to side effects¶ 0 (0.0) 1 (0.2) -
Minor side effects** 86 (30.0) 224 (75.7) 0.40 (0.33 to 0.48)
Palpitations†† 15 (5) 209 (71) 0.07 (0.04 to 0.12)
Dizziness‡‡ 25 (9) 55 (19) 0.47 (0.30 to 0.73)
Flushes§§ 17 (6) 99 (34) 0.18 (0.11 to 0.29)
Minor side effects were defined as one or a combination of: palpitations, nausea, vomiting, headaches, flushing, and dizziness.
*Missing data: n=402 for atosiban and n=399 for fenoterol owing to missing data.
†Missing data: n=392 for atosiban, n=390 for fenoterol.
‡Missing data: n=391 for atosiban, n=391 for fenoterol.
§Missing data: n=399 for atosiban, n=396 for fenoterol.
¶Missing data: n=399 for atosiban, n=396 for fenoterol.
**Missing data: n=287 for atosiban, n=296 for fenoterol.
††Missing data: n=287 for atosiban, n=296 for fenoterol.
‡‡Missing data: n=285 for atosiban, n=292 for fenoterol.
§§Missing data: n=287 for atosiban, n=295 for fenoterol.
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30 minutes after ECV (0.82, 0.69 to 0.98). After adjust-
ment for baseline characteristics the odds ratio for suc-
cessful ECV was 0.85 (0.72 to 1.02). The pooled result of 
the post hoc analysis indicated a consistent treatment 
effect and no heterogeneity was identified among cen-
tres (0.82, 0.69 to 0.98), I2=0%) (see supplementary 
appendix 1).
discussion
In this randomised controlled trial of 818 women with 
singleton pregnancies of more than 34 weeks’ gesta-
tion, uterine relaxation with atosiban for external 
cephalic version (ECV) resulted in a lower rate of fetuses 
in the cephalic position after 30 minutes compared with 
fenoterol. This led to a higher risk of caesarean deliver-
ies after atosiban treatment than after fenoterol treat-
ment. Although the difference was not statistically 
significant, the increased risk is highly plausible given 
the lower rate of successful ECV with atosiban.
strengths and limitations of this study
A beta mimetic rather than placebo was used for the 
control because at the start of the trial it was the best 
treatment in a clinical setting, with a 10% absolute 
increase in cephalic presentations at delivery.9  To allow 
the drugs to reach a full therapeutic blood concentra-
tion and to overcome unintended protocol violations, 
we used the same protocol for both drugs; ECV was 
started 15 minutes after the drug was given. The mean 
time for both drugs to reach their maximum concentra-
tions in serum is 30 minutes, with a half life of 1.4 hours 
for atosiban and 2 hours for fenoterol.13-17
A limitation of our study is that the doctors and the 
women could not be blinded to treatment owing to the 
obvious and common side effects of beta mimetics. 
However, side effects were never a reason for stopping 
the intervention, and bias due to non-blinding was vir-
tually absent.
Our success rate for cephalic presentations at 30 min-
utes after ECV was lower than anticipated,9  which 
might be due to the referral of some women after an ini-
tial unsuccessful attempt by independent midwives in 
an out of hospital setting. A cohort study of ECV 
attempts by midwives outside the hospital setting in the 
Netherlands reported a higher success rate than ours 
(1093 of 2318 women; 41%).18  The success rate in our 
study corresponds to that in other cohort studies and 
randomised controlled trials comparing tocolytic 
agents.10 11 19 20 Our sample size calculation was still ade-
quate to detect the anticipated increase in cephalic pre-
sentations at 30 minutes after ECV, as lower or higher 
baseline rates have more statistical power to detect sim-
ilar changes of 10% absolute risk difference.
Even though there was a difference in effect size 
between the imputed analysis and complete case anal-
ysis, the results are still likely to be generalisable. Miss-
ing data were balanced between groups and assumed to 
be random. We included a wide range of both positive 
and negative predictors for successful ECV in our impu-
tation model. Correction for confounding from poten-
tial baseline imbalance showed a strong correlation 
between baseline characteristics and successful ECV. 
Uterine relaxation might not be the strongest effector 
influencing the success rate of ECV.
After adjustment for potential baseline imbalance, 
the relative risk increased from 0.73 to 0.85, indicating a 
smaller magnitude of effect. However, the majority of 
the confidence intervals still favoured fenoterol.
Comparison with other studies
A Cochrane review on uterine relaxants for ECV con-
cluded that, compared with placebo, beta mimetics 
were the most effective drugs for increasing cephalic 
presentation in labour and thereby reducing the caesar-
ean section rate (six studies, 742 participants, relative 
risk 0.77, 95% confidence interval 0.67 to 0.88).9 Our 
results indicate that beta mimetics are the most effec-
tive in achieving cephalic presentation after ECV. More-
over, fenoterol is much cheaper than atosiban (€0.90 
(£0.80; $1.00) versus €31.80 in the Netherlands).
Our study clearly shows that fenoterol has more 
side effects than atosiban (71% v 5.2%). Discomfort 
due to palpitations was the most reported side effect, 
and severe hypotension occurred in one participant 
after taking fenoterol. Women must be adequately 
counselled about the side effects in relation to the 
effectiveness of beta mimetics, as evidence shows that 
women are willing to undergo treatment if the gain in 
success outweighs the possible adverse side effects.21 
In 2011, one in three deliveries in the US was by cae-
sarean section, making it the most common major 
surgical procedure for women in the country.22 23 
Without clear evidence of an accompanying decrease 
in maternal and neonatal morbidity or mortality, cae-
sarean delivery might be overused. Therefore, preven-
tion of planned caesarean section is one of the main 
ways to improve maternal and neonatal outcomes in 
current obstetric practice.6 24  Breech presentation is 
the third most common indication for primary caesar-
ean delivery in the US, and ECV is proven to be a safe 
procedure, so implementation of beta mimetics as the 
routine uterine relaxants for ECV should be high 
 priorty.25-28
Conclusion and policy implications
Fenoterol is more effective than atosiban for uterine 
relaxation before ECV. Fenoterol use is recommended to 
increase the success rate of ECV and decrease the cae-
sarean delivery rate.
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